Original Source(s)
Related Content
FDA approves XFG-adapted COVID-19 vaccine
The 2026 to 2027 formulation aligns with FDA guidance on the preferred composition for COVID-19 vaccines beginning this fall.
August 28, 2026
-
2 min
FDA expands essential thrombocythemia care
Phase 3 SURPASS ET data showed higher durable response rates with ropeginterferon alfa-2b-njft than with anagrelide.
September 1, 2026
-
2 min
FDA approves oral dermatomyositis therapy
Phase 3 findings show improvements in physical function and skin disease activity.
August 28, 2026
-
2 min